Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463541 · ClinicalTrials.gov registry record · Phase 3
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
A Phase 3 study of Urinary Bladder, Overactive, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,225
- Enrollment target
- 20
- Study locations
NCT00463541: Completed Phase 3 study of Urinary Bladder, Overactive, sponsored by Astellas Pharma.
NCT00463541 is a Phase 3 study of Urinary Bladder, Overactive that has completed, run by Astellas Pharma. The registered enrollment target is 2,225 participants, above the 117-participant average among 9 other Urinary Bladder, Overactive trials with a reported enrollment target (1802% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00463541, a Phase 3 study of Urinary Bladder, Overactive, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,225 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).
Conditions Studied
Interventions
- DRUG solifenacin succinate
Study Locations (20)
California
- - Beverly Hills
- - Buena Park
- - Corte Madera
- - Culver City
- - Fresno
- - Fullerton
- - Huntington Beach
Alabama
- - Bay Minette
- - Birmingham
- - Birmingham
- - Birmingham
- - Decatur
- - Huntsville
Arizona
- - Oro Valley
- - Phoenix
- - Phoenix
- - Scottsdale
- - Tucson
Arkansas
- - Little Rock
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,225 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00463541 record still lists
NCT00463541 is an interventional study that assigns participants to a tested intervention. Its 2,225 participants enrollment target places it among the larger protocols in the corpus, above the 117-participant average among 9 other Urinary Bladder, Overactive trials with a reported enrollment target (1802% higher).
The record links to 1 condition, with Urinary Bladder, Overactive appearing as the primary indexed condition, and to 1 intervention - of which solifenacin succinate is the first listed.
NCT00463541 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00463541 about?
NCT00463541 is a clinical study titled "Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms". To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).
What is the current status of trial NCT00463541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,225 participants. The study started on 2004-06. Estimated completion is 2005-04.
What conditions does trial NCT00463541 study?
This clinical trial studies the following conditions: Urinary Bladder, Overactive.
What interventions are being tested in trial NCT00463541?
The interventions under investigation include: solifenacin succinate (DRUG).
Who is sponsoring clinical trial NCT00463541?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00463541 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Bladder, Overactive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00463541's enrollment target sits among peer trials
2,225 1st of 9 higher than 9 of 9 other Urinary Bladder, Overactive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Bladder, Overactive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
ACTIVE NOT RECRUITING · Early Phase 1
-
INTIBIA Pivotal Study
ACTIVE NOT RECRUITING · NA
-
Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia